---
title: "Nuwellis (NUWE) news: reverse split and offering"
url: "https://aibio.space/companies/nuwellis/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "NUWE reverse split and offering news: Nuwellis sets one-for-nine reverse stock split effective October 26. Nuwellis, Inc. (NASDAQ: NUWE), United States."
---

NUWE Nuwellis, Inc. NASDAQ · United States

# Nuwellis (NUWE) news NUWE reverse split and offering news

Listings · 2026-10-22

## [Nuwellis sets one-for-nine reverse stock split effective October 26](https://aibio.space/news/nuwellis-sets-one-nine-reverse-stock-split-effective-october-26/)

The split takes effect at 5:00 p.m. Eastern Time on October 26, 2026, and NUWE shares trade split-adjusted from October 27.

## Latest Nuwellis news

1. 2026-08-26 Company Updates [Nuwellis investor presentation cites 20% first-half revenue growth](https://aibio.space/news/nuwellis-investor-presentation-cites-20-percent-first-half-revenue/) The August 2026 deck says first-half revenue rose 20% and that cash runway extends through 2Q27.
2. 2026-08-13 Company Updates [Nuwellis reports 14% second-quarter revenue growth and 76% gross margin](https://aibio.space/news/nuwellis-reports-14-percent-second-quarter-revenue-growth-76-percent/) Net sales were $2.0 million in the quarter, and the company says recent financings extend its cash runway through the second quarter of 2027.
3. 2026-07-31 Financings [Nuwellis prices $3.4 million registered direct offering at $2.59 a share](https://aibio.space/news/nuwellis-prices-3-4-million-registered-direct-offering-2-59-share/) Ladenburg Thalmann & Co. Inc. is the exclusive placement agent, and the deal includes warrants to buy up to 1,310,890 shares.
4. 2026-06-23 Listings [Nuwellis to effect one-for-thirty-five reverse stock split on June 25](https://aibio.space/news/nuwellis-effect-one-thirty-five-reverse-stock-split-june-25/) The split takes effect at 5:00 p.m. Eastern Time on June 25, 2026, and NUWE shares trade split-adjusted from June 26.
5. 2026-06-16 Company Updates [Nuwellis appoints Mike McCormick as chief executive officer](https://aibio.space/news/nuwellis-appoints-mike-mccormick-chief-executive-officer/) John Erb steps back from the executive role and remains Chairman of the Board, and the new chief executive takes over on June 30, 2026.
6. 2026-06-10 Debt Financing [BioRestorative sets up $1,000,000 revolving loan from Bowery Group](https://aibio.space/news/biorestorative-sets-up-1-000-000-revolving-loan-bowery-group/) BioRestorative Therapies can borrow up to $1,000,000 from Bowery Group LLC at 12%, and the same agreement brought three director resignations and three new directors designated by the lender. Its cash use in 2025 was $10.8 million.
7. 2026-06-08 Financings [Nuwellis closes $6.0 million public offering priced at $0.30 a share](https://aibio.space/news/nuwellis-closes-6-0-million-public-offering-priced-0-30-share/) Ladenburg Thalmann & Co. Inc. was sole book-running manager, and the deal included Series C warrants for up to 60,000,000 shares.
8. 2026-05-12 Company Updates [Nuwellis reports 26% first-quarter revenue growth and 70.1% gross margin](https://aibio.space/news/nuwellis-reports-26-percent-first-quarter-revenue-growth-70-1-percent/) Net sales were $2.4 million, and the company reported about $2.2 million of cash and no debt at March 31, 2026.

## Nuwellis at a glance

- **Ticker**: NUWE

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $3.9 million

### Related companies

- [MILESTONE SCIENTIFIC INC.](https://aibio.space/companies/milestone-scientific/) NYSE: MLSS
- [RetinalGenix Technologies](https://aibio.space/companies/retinalgenix-technologies/) OTC: RTGN
- [Sonendo](https://aibio.space/companies/sonendo/) OTC: SONX
- [SHOULDER INNOVATIONS, INC.](https://aibio.space/companies/shoulder-innovations/) NYSE: SI
- [CANNAPHARMARX, INC.](https://aibio.space/companies/cannapharmarx/) OTC: CPMD
- [NovoCure](https://aibio.space/companies/novocure/) NASDAQ: NVCR
- [LivaNova](https://aibio.space/companies/livanova/) NASDAQ: LIVN
- [CERUS CORP](https://aibio.space/companies/cerus/) NASDAQ: CERS

### Also on NASDAQ

- [Legend Biotech](https://aibio.space/companies/legend-biotech/) LEGN
- [Kiniksa Pharmaceuticals International](https://aibio.space/companies/kiniksa-pharmaceuticals-international/) KNSA
- [MannKind](https://aibio.space/companies/mannkind/) MNKD
- [Absci](https://aibio.space/companies/absci/) ABSI
- [Genelux](https://aibio.space/companies/genelux/) GNLX
- [MediciNova](https://aibio.space/companies/medicinova/) MNOV

## Nuwellis annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$8.3 million](https://www.sec.gov/Archives/edgar/data/1506492/000114036126009080/) | [$8.7 million](https://www.sec.gov/Archives/edgar/data/1506492/000114036126009080/) |
| Research and development | [$2.7 million](https://www.sec.gov/Archives/edgar/data/1506492/000114036126009080/) | [$3.2 million](https://www.sec.gov/Archives/edgar/data/1506492/000114036126009080/) |
| Net income (loss) | [-$17.5 million](https://www.sec.gov/Archives/edgar/data/1506492/000114036126009080/) | [-$11.2 million](https://www.sec.gov/Archives/edgar/data/1506492/000114036126009080/) |
| Cash from operations | [-$10.8 million](https://www.sec.gov/Archives/edgar/data/1506492/000114036126009080/) | [-$9.6 million](https://www.sec.gov/Archives/edgar/data/1506492/000114036126009080/) |
| Cash and equivalents | [$1.1 million](https://www.sec.gov/Archives/edgar/data/1506492/000114036126032810/) | [$5.1 million](https://www.sec.gov/Archives/edgar/data/1506492/000114036126009080/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.9 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Nuwellis

Did Nuwellis do a reverse stock split?

Our latest story on this, dated Oct 22, 2026: "Nuwellis sets one-for-nine reverse stock split effective October 26". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nuwellis-sets-one-nine-reverse-stock-split-effective-october-26/).

Has Nuwellis raised money recently?

Our latest story on this, dated Jul 31, 2026: "Nuwellis prices $3.4 million registered direct offering at $2.59 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nuwellis-prices-3-4-million-registered-direct-offering-2-59-share/).

What is the ticker symbol of Nuwellis?

Nuwellis, Inc. trades under the ticker NUWE on NASDAQ.

Where is Nuwellis listed?

Nuwellis, Inc. is listed on NASDAQ.

Which country or territory is Nuwellis listed under?

Our directory records Nuwellis, Inc. under United States.

Does aibio.space cover Nuwellis?

aibio.space lists Nuwellis, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was Nuwellis's revenue last year?

$8.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Nuwellis profitable?

Nuwellis, Inc. reported a net loss of $17.5 million for the fiscal year ended Dec 31, 2025, and used $10.8 million of cash in operations, per its annual report to the SEC.

How much does Nuwellis spend on research and development?

$2.7 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Nuwellis have?

$3.9 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest Nuwellis (NUWE) stock news?

Our latest story on Nuwellis, dated Oct 22, 2026: "Nuwellis sets one-for-nine reverse stock split effective October 26". The split takes effect at 5:00 p.m. Eastern Time on October 26, 2026, and NUWE shares trade split-adjusted from October 27. [Source](https://aibio.space/news/nuwellis-sets-one-nine-reverse-stock-split-effective-october-26/).

How long will Nuwellis's cash last?

From our story of Aug 26, 2026: The August 2026 deck says first-half revenue rose 20% and that cash runway extends through 2Q27. [Source](https://aibio.space/news/nuwellis-investor-presentation-cites-20-percent-first-half-revenue/).

Which other companies' news mentions Nuwellis?

Nuwellis is named in 1 of our story about other companies, most recently: "BioRestorative sets up $1,000,000 revolving loan from Bowery Group" (Jun 10, 2026). [Source](https://aibio.space/news/biorestorative-sets-up-1-000-000-revolving-loan-bowery-group/).

How can I follow Nuwellis (NUWE) news?

Press Follow on this page to add Nuwellis to your Following list, or subscribe to the aibio.space newsletter. We have published 9 stories naming Nuwellis so far, in Company Updates, Debt Financing, Financings, Listings.

## Investor discussion: Nuwellis

Members talk about Nuwellis (NUWE). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Nuwellis, newest first. Each line links the filing it comes from.

1. 2026-10-23 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506492/000114036126040605/ef20084194_8k.htm)
2. 2026-07-24 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1506492/000114036126029609/ef20078435_8k.htm)
3. 2026-07-07 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1506492/000153949726001914/n5983_x2-def14a.htm)
4. 2026-06-26 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1506492/000153949726001874/n5983_x1-sch14a.htm)
5. 2026-06-24 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506492/000114036126026114/ef20076614_8k.htm)
6. 2026-06-10 Listings Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506492/000114036126024740/ef20075871_ex99-1.htm)
7. 2026-06-08 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1506492/000114036126024372/ny20073226x4_424b4.htm)
8. 2026-05-22 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1506492/000114036126022629/ny20073226x1_s1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NUWE on TradingView](https://www.tradingview.com/symbols/NASDAQ-NUWE/).

## Listing details

Nuwellis, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NUWE, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Nuwellis, Inc.

- **Ticker**: NUWE

- **Listing**: NASDAQ

- **Country or territory**: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/nuwellis/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nuwellis (NUWE) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/nuwellis/